S. 891 (119th)Bill Overview

Bipartisan Health Care Act

Health|Health
Sponsor
Cosponsors
Support
Democratic
Introduced
Mar 6, 2025
Discussions
Bill Text
Current stageCommittee

Read twice and referred to the Committee on Finance.

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
Plain-English summaryWhat this bill actually does

A broad, bipartisan omnibus health bill that extends and modifies many Medicaid, Medicare, public health, FDA, and behavioral health authorities. Major elements include Medicaid home- and community-based services (HCBS) transparency and a limited HCBS expansion demonstration, Medicaid eligibility/residency and enrollment verifications, pharmacy payment and PBM transparency rules, numerous Medicare payment and telehealth extensions, program integrity measures, maternal care cost studies, and reauthorizations of public-health and opioid-response programs.

Why people may split

Progressives emphasize HCBS expansion and PBM accountability benefits.

Watch point

Relative to its intended legislative type, this bill is a well‑constructed substantive omnibus that amends numerous statutes to extend expiring provisions and create new programmatic requirements.

A broad, bipartisan omnibus health bill that extends and modifies many Medicaid, Medicare, public health, FDA, and behavioral health authorities.

Major elements include Medicaid home- and community-based services (HCBS) transparency and a limited HCBS expansion demonstration, Medicaid eligibility/residency and enrollment verifications, pharmacy payment and PBM transparency rules, numerous Medicare payment and telehealth extensions, program integrity measures, maternal care cost studies, and reauthorizations of public-health and opioid-response programs.

Many temporary waivers, payment add-ons, reporting requirements, and implementation timelines are set across Titles I–X.

Passage40/100

Content is largely technical extensions and targeted reforms which historically can pass, but scale, industry opposition, fiscal effects, and Senate approval hurdles lower standalone chances.

CredibilityPartially aligned

Relative to its intended legislative type, this bill is a well‑constructed substantive omnibus that amends numerous statutes to extend expiring provisions and create new programmatic requirements. The text generally supplies specific statutory language, definitions, deadlines, selection criteria, reporting duties, and some appropriations, and it integrates closely with existing law.

Contention62/100

Progressives emphasize HCBS expansion and PBM accountability benefits.

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens50% / 50%
StatesStates · Federal agencies

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • StatesStreamlined out-of-state provider enrollment may increase access to specialists for Medicaid-enrolled children.
  • Potential benefitHCBS transparency and demonstration grants could expand home-based services and reduce institutional care reliance.
  • Potential benefitMedicaid PBM pass-through and transparency rules aim to direct more drug payments to dispensing pharmacies.
Likely burdened
  • StatesNew reporting and verification duties will increase administrative costs for States, providers, and plans.
  • Federal agenciesFederal mandates on enrollee verification and pricing transparency increase federal oversight and may limit state flexi…
  • Potential burdenPBM restrictions and pass-through rules could reduce negotiating leverage, potentially raising plan costs or premiums.
03 · Why people split

Why the argument around this bill splits.

Progressives emphasize HCBS expansion and PBM accountability benefits.
Progressive88%

Likely broadly supportive.

The bill expands HCBS access, strengthens Medicaid protections for military families and people with disabilities, increases transparency of PBMs and pharmacies, and extends telehealth and public health programs.

Leans supportive
Centrist70%

Generally favorable but pragmatic and cautious.

Views the bill as a pragmatic package preserving services, extending pandemic-era flexibilities, and improving integrity, while raising questions about costs, administrative complexity, and state readiness.

Leans supportive
Conservative32%

Skeptical overall.

Supports anti-fraud and some provider protections, but worries about expanded federal mandates, regulatory complexity, PBM/market interventions, and added costs to states and federal budgets.

Likely resistant
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood40/100

Content is largely technical extensions and targeted reforms which historically can pass, but scale, industry opposition, fiscal effects, and Senate approval hurdles lower standalone chances.

Scope and complexity
86%
Scopesweeping
86%
Complexityhigh
Why this could stall
  • No CBO score or explicit net budget offset included
  • Level of organized industry (PBM/pharma/hospital) opposition
05 · Recent votes

Recent votes on the bill.

No vote history yet

The bill has not accumulated any surfaced votes yet.

06 · Go deeper

Go deeper than the headline read.

Included on this page

Progressives emphasize HCBS expansion and PBM accountability benefits.

Content is largely technical extensions and targeted reforms which historically can pass, but scale, industry opposition, fiscal effects, a…

Unlocked analysis

Relative to its intended legislative type, this bill is a well‑constructed substantive omnibus that amends numerous statutes to extend expiring provisions and create new programmatic requirements. The text generally sup…

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis